Flag of the European Union EU Clinical Trials Register Help

Clinical trials for 2-

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    38,656 result(s) found for: 2-. Displaying page 339 of 1,933.
    «« First « Previous 335  336  337  338  339  340  341  342  343  Next» Last»»
    EudraCT Number: 2014-004655-31 Sponsor Protocol Number: 1143-SCCHN-202 Start Date*: 2015-03-25
    Sponsor Name:Debiopharm International S.A.
    Full Title: Preoperative window-of-opportunity (WoO) study of Debio 1143 with or without cisplatin (CDDP) in patients with resectable squamous cell carcinoma of the head and neck.
    Medical condition: Squamous cell carcinoma of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-003599-39 Sponsor Protocol Number: AMD3100-3102-DE Start Date*: 2005-12-02
    Sponsor Name:AnorMED Corp.
    Full Title: A randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (240 mcg/kg) plus G-CSF (10 mcg/kg) versus G-CSF (10 mcg/kg) plus placebo to mobilize and collect greater than or equal ...
    Medical condition: Mobilization of stem cells prior to autologous stem cell transplantation in patients with multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001414-25 Sponsor Protocol Number: 205.417 Start Date*: 2008-08-20
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat ® inhaler (5 μg/day) over 48 ...
    Medical condition: Patients with severe persistent asthma who are still symptomatic despite being treated with high-dose inhaled corticosteroids and long-acting beta2-agonists. Additional asthma treatments are allowe...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049106 Asthma chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003932-11 Sponsor Protocol Number: I1F-MC-RHBV Start Date*: 2016-04-19
    Sponsor Name:Eli Lilly and Company
    Full Title: A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16 Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients with ...
    Medical condition: Radiographic Axial Spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10041672 Spondylitis ankylosing LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) PL (Completed) NL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-003685-32 Sponsor Protocol Number: PB-06-007 Start Date*: 2012-01-27
    Sponsor Name:Protalix Biotherapeutics
    Full Title: A Multicenter Extension Study of Taliglucerase alfa in Adult Subjects with Gaucher Disease
    Medical condition: Gaucher disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10018048 Gaucher's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-003018-17 Sponsor Protocol Number: SPD489-322 Start Date*: 2012-10-10
    Sponsor Name:Shire Development LLC
    Full Title: The SPD489-322 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-005617-36 Sponsor Protocol Number: TESEC-06 Start Date*: 2012-05-30
    Sponsor Name:Statens Serum Institut
    Full Title: A phase III contact tracing trial comparing the diagnostic performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in combination with a double blind randomized split body safety assessment of C-Tb ve...
    Medical condition: Tuberculosis diagnostic tool
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10044755 Tuberculosis PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-005556-25 Sponsor Protocol Number: OFT-ETAMSILATO-4.2.2 Start Date*: 2015-05-11
    Sponsor Name:Investigacion Independiente
    Full Title: Open extension study for patients with age related macula degeneration who participated in the Fase IV-II clinical trial randomized, simulatedcontrolled treatment to evaluate safety and efficacy o...
    Medical condition: Aged related macula degeneration (ARMD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-004210-26 Sponsor Protocol Number: 14/0647 Start Date*: 2016-11-22
    Sponsor Name:PRIMENT Clinical Trials Unit, UCL
    Full Title: A Phase IV double blind multi-site, individually randomised parallel group controlled trial investigating the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in pati...
    Medical condition: Depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000024331 10066555 Chronic depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001807-18 Sponsor Protocol Number: TD-0903-0188 Start Date*: 2020-05-18
    Sponsor Name:Theravance Biopharma Ireland Limited
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-center Study of an Inhaled Pan-Janus Kinase Inhibitor, TD-0903, to Treat Symptomatic Acute Lung Injury Associated with...
    Medical condition: Acute lung injury associated with COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004855 10047468 Viral lower respiratory tract infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) RO (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2017-004022-15 Sponsor Protocol Number: ANB019-003 Start Date*: 2020-04-21
    Sponsor Name:AnaptysBio Inc
    Full Title: A Phase 2, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects with Palmoplantar Pustulosis
    Medical condition: Palmoplantar pustulosis (PPP)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004858 10037159 Psoriasis pustular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004255-70 Sponsor Protocol Number: 205687 Start Date*: 2017-05-29
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, parallel group PhIII study to assess the clinical efficacy and safety of 100 mg SC Mepolizumab as an add on to maintenance treatment in adults with severe bilateral nasa...
    Medical condition: Treatment of nasal polyposis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10028756 Nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) SE (Completed) NL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-014980-38 Sponsor Protocol Number: TJB0909P1 Start Date*: 2010-07-06
    Sponsor Name:CHU de Liège
    Full Title: Co-transplantation of mesenchymal stem cells and HLA-mismatched allogeneic hematopoietic cells after reduced-intensity conditioning: a phase II randomized double-blind study.
    Medical condition: Hematological malignancies confirmed histologically and not rapidly progressing: - AML in Complete Remission; - ALL in Complete Remission; - CML unresponsive/intolerant to Imatinib but not in b...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10027703 Mismatched donor bone marrow transplantation therapy PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001305-41 Sponsor Protocol Number: MicroVasc-DIVA Start Date*: 2014-11-25
    Sponsor Name:GWT-TUD GmbH
    Full Title: MICROVASCULAR AND ANTIINFLAMMATORY EFFECTS OF RIVAROXABAN COMPARED TO LOW DOSE ASPIRIN IN TYPE 2 DIABETIC PATIENTS WITH VERY HIGH CARDIOVASCULAR RISK AND SUBCLINICAL INFLAMMATION
    Medical condition: Patients with type 2 diabetes and stable cardiovascular disease (CVD) and low grade inflammation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004483-38 Sponsor Protocol Number: TMP001_MS Start Date*: 2015-07-16
    Sponsor Name:Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME)
    Full Title: TMP001 in relapsing-remitting multiple sclerosis: a multicentre open, baseline-controlled phase IIa clinical trial
    Medical condition: Patients with defined diagnosis of relapsing-remitting multiple sclerosis and at least 1 documented relapse during the previous year OR at least 2 documented relapses during the previous 2 years.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003672-12 Sponsor Protocol Number: TM005 Start Date*: 2019-01-29
    Sponsor Name:Saniona A/S
    Full Title: A 24-week phase 2, double-blind, randomized, placebo-controlled, single-centre safety and efficacy study to evaluate overall safety and tolerability of co-administration of tesofensine and metoprol...
    Medical condition: Hypothalmic injury-induced obesity (HIO)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004860 10013367 Disorders of the pituitary gland and its hypothalamic control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-001957-17 Sponsor Protocol Number: DFNS02 Start Date*: 2015-10-21
    Sponsor Name:Umeå University Hospital
    Full Title: THE EFFECT OF DIFLUNISAL ON FAMILIAL TRANSTHYRETIN AMYLOIDOSIS: An open label phase III extension study of the diflunisal trials (IND 68092 and DFNS01), and an open label observational study on p...
    Medical condition: Familial transthyretin amyloidosis complicated by cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004850 10019893 Hereditary neuropathic amyloidosis, Swedish type LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000934-32 Sponsor Protocol Number: AVXCLIN005 Start Date*: 2021-10-25
    Sponsor Name:Coegin Pharma AB
    Full Title: A single-center, randomized double-blind, vehicle-controlled, dose-ranging decentralised clinical trial to evaluate the safety and efficacy of daily field-directed topical applications of AVX001 s...
    Medical condition: Actinic Keratosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002042-21 Sponsor Protocol Number: PMT4979g Start Date*: 2015-02-19
    Sponsor Name:Genentech, Inc.
    Full Title: AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS AND IN COMBINATION WITH ENDOCRINE TH...
    Medical condition: Patients with locally advanced or metastatic solid tumors and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000346-18 Sponsor Protocol Number: BST-SCI-02 Start Date*: 2021-06-28
    Sponsor Name:Banc de Sang i Teixits
    Full Title: A phase I/II, randomized, double-blind, placebo-controlled, parallel, 2-arms clinical trial to assess the safety and efficacy of intrathecal administration of WJ-MSC in chronic traumatic cervical i...
    Medical condition: Cronic traumatic spinal cord injury
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022117 - Injury, poisoning and procedural complications 10041554 Spinal cord injury cervical PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 335  336  337  338  339  340  341  342  343  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Feb 11 21:59:44 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA